Title: |
A framework of biomarkers for skeletal msucle aging: a consensus statement by the Aging Biomarker Consortium(2024) |
Edition: |
Original |
Classification: |
Experts consensus |
Field: |
Diagnosis |
Countries and regions: |
China |
Guidelines users: |
Researchers and clinicians in the field of skeletal muscle aging, as well as practitioners in the medical and health sectors. |
Evidence classification method: |
European Society of Cardiology Standard
LEVEL (QUALITY) OF EVIDENCE
Level A: Data derived from multiple randomized clinical trials or meta-analyses
Level B:Data derived from a single randomized clinical trial or large non-randomized studies
Level C:Consensus of expert opinion, and/or small studies, retrospective studies, registries
CLASS (STRENGTH) OF RECOMMENDATION
CLASS I (STRONG) : Benefit >>> Risk,Recommended/Indicated,Evidence and/or general agreement that a given treatment or procedure is beneficial, useful and effective
CLASS IIa (MODERATE) :Benefit >> Risk,Should be considered, Weight of evidence/opinion is in favour of usefulness/efficacy
CLASS IIb (WEAK) :Benefit ≥ Risk,May be considered,Usefulness/efficacy is less well established by evidence/opinion
CLASS III (Strong):Risk > Benefit,Not recommended,Evidence/general agreement that the given treatment/procedure is not useful/effective and sometimes maybe harmful
|
Development unit: |
West China Hospital of Sichuan University,Bioland Laboratory,College of Life Sciences,State Key Laboratory of Membrane Biology,Chinese Academy of Medical Sciences and School of Basic Medicine,the Fourth Medical Center of PLA General Hospital |
Registration time: |
2024-04-19 |
Registration number: |
PREPARE-2024CN552 |
Purpose of the guideline: |
This expert consensus aims to summarize the biomarkers related to skeletal muscle aging reported in previous studies from three dimensions: skeletal muscle function, structure, and body fluids. It is hoped that through these biomarkers, the degree of skeletal muscle aging can be accurately determined and the effects of aging interventions can be evaluated. |